Cargando…
Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2
BACKGROUND: VEGF is a highly selective mitogen that serves as the central regulator of tumor angiogenesis by mediating endothelial proliferation, permeability, and survival. Tanibirumab (TTAC-0001) is a fully human IgG1 monoclonal antibody derived from a fully human naïve single-chain variable fragm...
Autores principales: | Lee, Weon Sup, Shim, Sang Ryeol, Lee, Seon Young, Yoo, Jin San, Cho, Sung Kweon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848842/ https://www.ncbi.nlm.nih.gov/pubmed/29563774 http://dx.doi.org/10.2147/DDDT.S150241 |
Ejemplares similares
-
Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis
por: Kim, Dong Geon, et al.
Publicado: (2015) -
Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model
por: Kim, Jinil, et al.
Publicado: (2018) -
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
por: Lee, Su Jin, et al.
Publicado: (2017) -
Interspecies extrapolation by physiologically based pharmacokinetic modeling
por: Ghallab, Ahmed
Publicado: (2015) -
Highlight report: Interspecies extrapolation by physiologically based pharmacokinetic modeling
por: Widera, Agata
Publicado: (2015)